Send to

Choose Destination
Trends Biotechnol. 1998 Dec;16(12):513-20.

Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis.

Author information

Technion-Israel Institute of Technology, Haifa.


Recombinant immunotoxins are new agents being developed for cancer therapy. They are composed of Fv fragments of antibodies that bind to cancer cells fused to a truncated form of a very potent bacterial toxin. The antibody moiety directs the toxin to cancer cells, which are killed, while normal cells are not recognized and thus survive. The excellent preclinical results in vitro and in vivo have led to the initiation of several clinical trials.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center